Evidence map›Paper›PMID 33758833›Full record

ArticleResearch square2021

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.

Aljawharah Alrubayyi, Ester Gea-Mallorquí, Emma Touizer, Dan Hameiri-Bowen, Jakub Kopycinski, Bethany Charlton, Natasha Fisher-Pearson, Luke Muir, Annachiara Rosa, Chloe Roustan and 11 more

Open access · greenAbstract readPreprint
In one paragraph

Article in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 11 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 1 country.

Aljawharah AlrubayyiNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Ester Gea-MallorquíNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Emma TouizerDivision of Infection and Immunity, University College London, London, United Kingdom.
Dan Hameiri-BowenNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Jakub KopycinskiNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Bethany CharltonNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Natasha Fisher-PearsonNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Luke MuirDivision of Infection and Immunity, University College London, London, United Kingdom.
Annachiara RosaChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.
Chloe RoustanChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.
Christopher EarlChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.
Peter CherepanovChromatin Structure and Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.
Pierre PellegrinoMortimer Market Centre, Department of HIV, CNWL NHS Trust, London, United Kingdom.
Laura WatersMortimer Market Centre, Department of HIV, CNWL NHS Trust, London, United Kingdom.
Fiona BurnsInstitute for Global Health UCL, London, United Kingdom.
Sabine KinlochRoyal Free London NHS Foundation Trust, London, United Kingdom.
Tao DongNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Lucy DorrellNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Sarah Rowland-JonesNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
Laura E McCoyDivision of Infection and Immunity, University College London, London, United Kingdom.
Dimitra PeppaNuffield Dept of Clinical Medicine, University of Oxford, United Kingdom.
University of Oxford · GBThe Francis Crick Institute · GBUniversity College London · GBMortimer Market Centre · GBRoyal Free London NHS Foundation Trust · GB

Funding

Exploiting Natural Killer cells in HIV/HBV co-infection to achieve eradicationR01AI155182 · NIAID · UNIVERSITY OF OXFORD · PI PEPPA, DIMITRA · 2020 to 2024
$1.9M
Medical Research Council MR/L018942/1NIAID NIH HHS R01 AI155182
6 · The paper itself

Abstract

There is an urgent need to understand the nature of immune responses against SARS-CoV-2, to inform risk-mitigation strategies for people living with HIV (PLWH). We show that the majority of PLWH, controlled on ART, mount a functional adaptive immune response to SARS-CoV-2. Humoral and SARS-CoV-2-specific T cell responses are comparable between HIV-positive and negative subjects and persist 5-7 months following predominately mild COVID-19 disease. T cell responses against Spike, Membrane and Nucleocapsid are the most prominent, with SARS-CoV-2-specific CD4 T cells outnumbering CD8 T cells. We further show that the overall magnitude of SARS-CoV-2-specific T cell responses relates to the size of the naive CD4 T cell pool and the CD4:CD8 ratio in PLWH, in whom disparate antibody and T cell responses are observed. These findings suggest that inadequate immune reconstitution on ART, could hinder immune responses to SARS-CoV-2 with implications for the individual management and vaccine effectiveness in PLWH.

Identifiers

PMID33758833
PMCPMC7987102
OpenAlexW4230146239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.